International Deprescribing Journal Club
About the International Deprescribing Journal Club
The Canadian Medication Appropriateness and Deprescribing Network works with international partners to host the journal club’s quarterly sessions. This journal club is for clinicians and researchers around the globe looking to connect and discuss recent deprescribing publications and complex clinical cases.
Goals of the International Deprescribing Journal Club
Strengthen partnerships among international deprescribing networks
Stay current with the literature and share knowledge
Build momentum and collaboration to facilitate larger international deprescribing trials showing impacts of deprescribing
Session topics & format
Content includes deprescribing case studies, recent literature, or a combination of both
Sessions last approximately 50 to 60 minutes, including a minimum of 20 minutes of Q&A
Sessions are recorded and posted on the Canadian Medication Appropriateness and Deprescribing Network’s YouTube channel.
Title: TBD
Speaker:
Upcoming session
Research Assistant Professor, Cedars-Sinai, Health Services Research
Adjunct Assistant Professor, University of California, Health Policy and Management
Date and time: Thursday, December 12, 2024 @10:00 am - 11:00 am (San Francisco, USA)
Other time zones: Thursday, December 12, 2024 @1:00 pm - 2:00 pm (Montréal, Canada)
Thursday, December 12, 2024 @5:00 - 6:00 pm (London, UK)
Friday, December 13, 2024 @5:00 am - 6:00 am (Melbourne, Australia)
Host: US Deprescribing Research Network
Moderator: Roni Kraut (MD, MSc)
Dr. Roni Kraut is an assistant professor in the Department of Family Medicine at the University of Alberta, completing a RCT on deprescribing antihypertensives in long-term care, and a member of the Canadian Medication Appropriateness and Deprescribing Netowork research committee
Past sessions
Reducing inappropriate prescribing in older adults: Lessons learned from Swiss primary care settings
Presented by: Dr. Katharina Tabea Jungo
Hosted by: Network of European Researchers in Deprescribing (NERD)
Date: Oct 30, 2024
Dr. Jungo discussed the article Optimising prescribing in older adults with multimorbidity and polypharmacy in primary care (OPTICA): cluster randomised clinical trial, including findings of the health economic analysis and the implementation evaluation conducted alongside the OPTICA trial.
Measurement issues in medication safety: what matters, what data do we have and how do we evaluate cost effectiveness?
Description: Dr. Spinks discussed the article Activating pharmacists to reduce the frequency of medication-related problems (ACTMed) : a stepped wedge cluster randomised trial.
Prescribing Cascades: Identifying, Managing, and Preventing the Domino Effect
Presented by: Dr. Kieran Dalton and Dr. Lisa McCarthy
Hosted by: European Society of Clinical Pharmacy
Date: March 6, 2024
Description: Prescribing cascades can be difficult to identify in clinical practice. Even if they are identified, it is not always clear on how to address them. This session provides an overview of key research to help inform the focus and design of guidance, tools, and interventions to minimise the occurrence of prescribing cascades in patients.
Deprescribing educational framework : challenges for implementation and educational scholarship
Presented by: Dr. Barbara Farrell, Dr. Lalitha Raman-Wilms, and Dr. Cheryl A. Sadowski
Hosted by: Canadian Medication Appropriateness and Deprescribing Network
Date: December 6, 2023
Description : You know about deprescribing, but have you thought about how you are teaching it? Based on the first international interprofessional deprescribing curricular framework, the lead authors will share the highlights and discuss application.
Lessons from a pilot of ALIGN: Aligning Medications with What Matters Most
Description: ALIGN is a pragmatic, pharmacist-led telehealth intervention in primary care to optimize medications for people living with dementia and reduce inappropriate polypharmacy by focusing on what matters most to patients and care partners. Dr. Green will present on key learnings from the ALIGN pilot, implementation successes and challenges, and plans for a full-scale embedded pragmatic clinical trial.
COFRAIL and Deprescribing Inappropriate PPIs Trials
Presented by: Dr. Achim Mortsiefer and Dr. Kristie Weir
Hosted by: Network of European Researchers in Deprescribing
Date: June 19, 2023
Click here to download slides - COFRAIL Trial (PDF)
Click here to download slides - Deprescribing Inappropriate PPIs Trial (PDF)
Description: Dr. Achim Mortsiefer presents Family Conferences to Facilitate Deprescribing in Older Outpatients With Frailty and With Polypharmacy: The COFRAIL Cluster Randomized Trial. To learn more on the COFRAIL Trial, click here.
Dr. Kristie Weir presents Deprescribing Inappropriate PPIs: Developing an Intervention and Planning a Trial.
Clinical outcomes of sedative deprescribing within RedUSe and implications for practice
Description: This session discussed the RedUSe study published in International Psychogeriatrics, with reference to more contemporary literature/clinical guidelines when discussing the implications of the findings.
Initial findings from the iSIMPATHY project and experiences of implementation
Presented by: iSIMPATHY Project Team
Hosted by: European Society of Clinical Pharmacy
Date: Dec 1, 2022
Description: iSIMPATHY (implementing Stimulating Innovation in the Management of Polypharmacy and Adherence Through the Years) is an EU funded partnership between Ireland, Scotland and Northern Ireland delivering person-centred, pharmacist-led medication reviews across primary and secondary care.
Pharmacist representatives from the iSIMPATHY project in each of the three countries presented the project data to date and also reflected on the implementation of iSIMPATHY in their own areas.
The OPTIMIZE Trial: A Clinician’s Reflection on the Challenges of Deprescribing
Presented by: Louise Papillon-Ferland, B.Pharm., M.Sc.
Hosted by: Canadian Medication Appropriateness and Deprescribing Network
Date: October 5, 2022
Description:
Session objectives:
1. Present key learnings from the OPTIMIZE trial.
2. Discuss enablers and barriers of deprescribing, as applied to real-life clinical cases.